Cetuximab biosimilar - R-Pharm

Drug Profile

Cetuximab biosimilar - R-Pharm

Alternative Names: Erbitux biosimilar - R-Pharm; RPH 002

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator R-Pharm
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 04 Sep 2017 Cetuximab biosimilar is still in clinical trials for Head and neck cancer (R-Pharm pipeline, August 2017)
  • 15 May 2015 R-Pharm announces intention to submit MAA in Russia and Turkey in 2015
  • 11 May 2015 Phase III clinical trials in Head and neck cancer (Metastatic disease, Recurrent, Treatment-resistant) in Turkey (IV) before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top